Physician profile
Edward Leroy
NPI 1508992660
$12,176.60
in general payments reported to CMS, 2019-2025
43 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 88% of Spinal Cord Injury Medicine providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $1,281 · 2021: $2,744 · 2022: $1,911 · 2023: $2,268 · 2024: $1,434 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,869.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $2,598.91 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,606.25 | 2019-2025 | Relistor |
| Abbvie INC. | $1,182.87 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $682.61 | 2019-2020 | |
| Pfizer INC. | $502.75 | 2019-2025 | |
| Biodelivery Sciences International, INC. | $464.60 | 2019-2021 | |
| Eisai INC. | $441.93 | 2020-2022 | |
| Averitas Pharma INC. | $389.89 | 2023-2024 | Qutenza |
| Medtronic, INC. | $387.08 | 2021-2024 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $360.73 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $343.38 | 2020-2023 | Belsomra |
| Biohaven Pharmaceuticals, INC. | $318.92 | 2021 | |
| Nevro Corp. | $276.01 | 2022-2023 | Senza |
| Astrazeneca Pharmaceuticals LP | $240.00 | 2021-2022 | |
| Grt US Holding, INC. | $213.35 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Leroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.